Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

NCT00848029 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
240
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Vaccines